Gingival crevicular fluid MMP-8 and -13 and TIMP-1 levels in patients with rheumatoid arthritis and inflammatory periodontal disease.
BACKGROUND
The purpose of this study was to compare gingival crevicular fluid (GCF) levels of matrix metalloproteinase (MMP)-8 and -13 and tissue inhibitor of MMP (TIMP)-1 in patients with rheumatoid arthritis (RA) and systemically healthy counterparts with inflammatory periodontal disease.


METHODS
Subjects (N = 74) were divided into five groups: 12 patients with RA and gingivitis; 13 patients with RA and periodontitis; 12 systemically healthy patients with gingivitis; 13 systemically healthy patients with periodontitis; and 24 periodontally and systemically healthy volunteers. Full-mouth clinical periodontal measurements were performed at six sites/tooth. GCF samples obtained from two sites in single-rooted teeth were analyzed by immunofluorometric assay and enzyme-linked immunosorbent assay. Data were assessed statistically by parametric tests.


RESULTS
The total amounts of MMP-8 were lower in the healthy control group than in RA-gingivitis, RA-periodontitis, and healthy-periodontitis groups (P <0.05). MMP-13 levels were similar in all five study groups (P >0.05). Patients with RA and gingivitis or periodontitis exhibited levels of MMP-8 and -13 and TIMP-1 that were similar to systemically healthy counterparts (P >0.05).


CONCLUSIONS
The coexistence of RA and periodontitis did not significantly affect the investigated parameters. GCF MMP-8 levels increased with periodontal inflammation. Despite the long-term usage of corticosteroids and non-steroidal anti-inflammatory drugs, similar GCF MMP-8 and -13 levels in patients with RA and systemically healthy counterparts suggest that RA may create a tendency to overproduce these enzymes.
Biyikoğlu
Başak
B
Department of Periodontology, School of Dentistry, Ege University, Izmir, Turkey.
Buduneli
Nurcan
N
Kardeşler
Levent
L
Aksu
Kenan
K
Pitkala
Marjut
M
Sorsa
Timo
T
D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000150:complications / Q000201:enzymology*; D001799:Blood Sedimentation; D002097:C-Reactive Protein / Q000032:analysis; D003774:Dental Plaque Index; D005260:Female; D005883:Gingival Crevicular Fluid / Q000201:enzymology*; D005891:Gingivitis / Q000150:complications / Q000201:enzymology; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000097:blood; D008297:Male; D053509:Matrix Metalloproteinase 13 / Q000032:analysis*; D020784:Matrix Metalloproteinase 8 / Q000032:analysis*; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D017622:Periodontal Attachment Loss / Q000145:classification; D010512:Periodontal Index; D010514:Periodontal Pocket / Q000145:classification; D010518:Periodontitis / Q000145:classification / Q000150:complications / Q000201:enzymology*; D010519:Periodontium / Q000201:enzymology; D011239:Prednisolone / Q000627:therapeutic use; D012217:Rheumatoid Factor / Q000097:blood; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000032:analysis*
D018501:Antirheumatic Agents; D005938:Glucocorticoids; D007155:Immunologic Factors; D019715:Tissue Inhibitor of Metalloproteinase-1; D002097:C-Reactive Protein; D012217:Rheumatoid Factor; D011239:Prednisolone; C507079:MMP13 protein, human; D053509:Matrix Metalloproteinase 13; C488762:MMP8 protein, human; D020784:Matrix Metalloproteinase 8; D008727:Methotrexate